elder law weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of elder law weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dynavax Technologies Corporation
Full enrollment reported in phase II/III AIC trial
June 23rd, 2004
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, announced that its phase II/III clinical trial of AIC for ragweed allergy, which started in late February 2004, has been fully enrolled. The double blind, placebo controlled study involves 462 subjects at 30 sites in the U.S. and will be completed over the next 18 months. The immunization schedule, consisting of six injections over 6 weeks, will be completed by June. The clinical trial is being conducted in collaboration with UCB...
Source: elder law weekly (2004-06-23)
|
